[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Bădulescu F, Bădulescu A, Schenker M, Popescu CF, Stoica Z: The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma. Rom J Morphol Embryol; 2005;46(4):329-34
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
  • PURPOSE: The purpose of this study is to compare the predicted value of the blood levels variations of CA 125 antigen and the imunohistochemical expression of CA 125, with imagistic criteria (The Response Evaluation Criteran in Solid Tumor--RECIST) regarding the survival estimation of female patients with relapsed ovarian carcinoma which undergo to second line chemotherapy.
  • MATERIAL AND METHOD: We included in this study 40 female patients diagnosed with ovarian carcinoma in the Oncology Clinic of the Emergency County Hospital Craiova, in a period of two years (from 2000 to 2002), which have fulfilled the following criteria: ovarian carcinoma IC-IV stage, according to FIGO system, first line treatment represented by the association between paclitaxel and a platinum salt, refractory or recurrent disease, indications for beginning the second line chemotherapy represented by topotecan or paclitaxel and carboplatin.
  • The serial CA 125 antigen was determined in all patients before starting the chemotherapy and after each two sequences of chemotherapy, and the imunohistochemical expression of CA 125 was evaluated from surgery extracts before the second line chemotherapy (11 cases).
  • The imagistic evaluation of the treatment response was done after 4 sequences of chemotherapy.
  • RESULTS: All patients had measurable disease according to RECIST criteria and had high values (at least double) of the CA 125 antigen blood level at the time of diagnosis.
  • In a various analysis, which included numerous potential prognostic factors, only the variation of blood levels of these antigen and the free disease interval from the finalization of the first line chemotherapy have been identified as predictive factors of survival, while the other variables, including the RECIST criteria, had no impact on the prognosis regarding the survival.
  • CONCLUSIONS: The response evaluation criteria based on the blood levels variations of CA 125 antigen are a better instrument for the estimation of the compared prognosis with the RECIST criteria, for patients on second line chemotherapy for relapsed ovarian carcinoma.
  • [MeSH-major] CA-125 Antigen / analysis. CA-125 Antigen / blood. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Cystadenocarcinoma, Mucinous / chemistry. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Papillary / chemistry. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / chemistry. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Drug Resistance, Neoplasm. Female. Humans. Immunohistochemistry. Paclitaxel / therapeutic use. Platinum Compounds / therapeutic use. Topotecan / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16688372.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Platinum Compounds; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


2. Gronlund B, Hansen HH, Høgdall C, Engelholm SA: Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer; 2002 Oct 15;95(8):1656-62
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
  • Food and Drug Administration-approved topotecan dose of 1.5 mg/m(2) for 5 days every 3 weeks may have limited its utility in the treatment of patients with epithelial ovarian carcinoma.
  • The objective of the study was to evaluate the treatment results and toxicity of a low-dose topotecan regimen as second-line treatment for patients with epithelial ovarian carcinoma.
  • METHODS: A retrospective analysis was conducted of 203 consecutive patients with primary epithelial ovarian carcinoma who were referred to the Finsen Center during the period from June, 1996 to June, 2000.
  • Eligibility criteria included histopathologically documented, International Federation of Gynecology and Obstetrics (FIGO) Stage IC-IV epithelial ovarian carcinoma; first-line treatment with paclitaxel and a platinum compound; and second-line treatment with topotecan (1.0 mg/m(2) intravenously for 5 days every 3 weeks).
  • RESULTS: A total of 56 patients received second-line treatment with the reduced-dose topotecan regimen because of refractory, persistent, or recurrent disease.
  • In patients with platinum-resistant and paclitaxel-resistant disease, the median progression free survival and overall survival from the first day of second-line topotecan treatment were 2.7 months (range, 0.7-19.5 months) and 6.0 months (range, 1.0-32.8 months), respectively.
  • In a multivariate Cox analysis, the initial performance status (0 vs. 1-2; P = 0.040; hazard ratio [HR], 2.05) and the performance status at the time of second-line treatment (0 vs. 1-2; P < 0.001; HR, 4.50) were identified as independent prognostic factors for overall survival from the start of second-line treatment.
  • CONCLUSIONS: Topotecan at a dose of 1.0 mg/m(2) has similar efficacy based on response rate and lower toxicity compared with the approved schedule of 1.5 mg/m(2) for 5 days every 3 weeks in second-line treatment for patients with platinum-resistant and paclitaxel-resistant epithelial ovarian carcinoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacology. Carcinoma / drug therapy. Ovarian Neoplasms / drug therapy. Topotecan / administration & dosage. Topotecan / pharmacology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Cisplatin / pharmacology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12365013.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Gronlund B, Høgdall C, Hansen HH, Engelholm SA: Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer; 2002 Apr 1;94(7):1961-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.
  • BACKGROUND: Intravenous cytostatic agents as second-line treatment of epithelial ovarian carcinoma have been withheld from many elderly patients because of fear of toxicity.
  • The purpose of the study is to compare the toxicity and efficacy between elderly (older than 65 years of age) and younger (younger than 65 years of age) patients receiving intravenous second-line treatment of epithelial ovarian carcinoma.
  • METHODS: This study was a retrospective analysis of 286 consecutive patients with primary epithelial ovarian carcinoma.
  • Inclusion criteria included histopathologically documented International Federation of Gynecology and Obstetrics (FIGO) Stage IC-IV epithelial ovarian carcinoma; first-line treatment with paclitaxel and a platinum analog; intravenous second-line treatment with topotecan 1.0 mg/m(2)/day for 5 days, every 3 weeks or paclitaxel (175 mg/m(2)) and carboplatin (AUC 5), every 3 weeks.
  • The patients' age at start of second-line treatment in the younger (n = 68) and the elderly (n = 34) group were median 54.0 years (range, 34.7-64.3) and 69.5 years (range, 65.1-77.2), respectively.
  • The overall survival from the first day of second-line treatment in patients aged younger and older than 65 years were median 13.3+ months (range, 1.2-38.3+) and 11.8+ months (range, 2.0-41.0+), respectively (P = 0.25).
  • In a multivariate Cox analysis, performance status at time of first-line treatment (0 vs.1-2; P = 0.013; hazard ratio [HR], 2.12), performance status at time of second-line treatment (0 vs. 1-2; P = 0.004; HR, 2.47), and response to second-line treatment (CR + PR vs. NC + PD; P < 0.001; HR, 4.38) were found to be independent significant factors for overall survival whereas age (younger than 65 years vs. older than 65 years) yielded no independent information (P = 0.90).
  • No differences in the rate of postponement of treatment, neutropenia Grade 4, thrombocytopenia Grade 3-4, nor hypersensitivity reaction to either cytostatic agent between older and younger patients were noticed (P > 0.05).
  • CONCLUSIONS: Modality of second-line treatment of epithelial ovarian carcinoma should be determined more by assessment of performance status than age per se.
  • Second-line treatment with topotecan or paclitaxel-carboplatin can be safely administered in the aged.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Age Factors. Aged. Aging / physiology. Carboplatin / administration & dosage. Carboplatin / adverse effects. Epithelial Cells / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Retrospective Studies. Survival Rate. Topotecan / administration & dosage. Topotecan / adverse effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11932898.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. Kawagishi N, Shirahata Y, Ishida K, Satoh K, Enomoto Y, Akamatsu Y, Sekiguchi S, Fukumori T, Fujimori K, Satoh A, Moriya T, Satomi S: Hepatic resection of giant metastatic tumor from clear cell carcinoma of the ovary. J Hepatobiliary Pancreat Surg; 2005;12(2):155-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection of giant metastatic tumor from clear cell carcinoma of the ovary.
  • All cancer patients, particularly those treated for colorectal cancer, should be monitored for the presence of liver metastases, but liver metastases from ovarian clear cell carcinoma are quite rare.
  • We report a patient subjected to extended left hepatectomy due to a giant metastasis 5 years after surgical treatment for an ovarian neoplasm that was histopathologically diagnosed as clear cell carcinoma.
  • A 58-year-old woman had undergone hysterectomy and bilateral salpingo-oophorectomy due to ovarian cancer (stage Ic).
  • Four years and 8 months after the operation, a computed tomography (CT) scan demonstrated a giant tumor in the left lobe of the liver.
  • She received chemotherapy for 4 months; however, the tumor did not decrease in size.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / secondary. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868082.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Battaglia F, Plotti F, Zullo MA, Panici PB, Plotti G: Successful pregnancy after conservative surgery for stage IC ovarian cancer with serous borderline tumor on controlateral ovary: a case report. Gynecol Oncol; 2006 Mar;100(3):612-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful pregnancy after conservative surgery for stage IC ovarian cancer with serous borderline tumor on controlateral ovary: a case report.
  • BACKGROUND: In invasive ovarian cancer, fertility saving surgery is confined to early-stage and low-grade disease, and only few study reported sparing fertility up to FIGO stage IC ovarian cancer.
  • CASE: We present a rare case of a 30-year-old woman affected by IC ovarian cancer with borderline tumor on controlateral ovary who underwent "conservative" debulking surgery followed by adjuvant chemotherapy.
  • CONCLUSIONS: Nowadays, preservation of ovarian function in women with tumors in early stage should be evaluated for conservative surgery.
  • Careful follow-up is mandatory to ensure safety of this procedure.
  • [MeSH-major] Live Birth. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Fertility. Humans. Pregnancy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249017.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Protopapas A, Diakomanolis E, Bamias A, Milingos S, Markaki S, Papadimitriou C, Dimopoulos AM, Michalas S: The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy. Eur J Gynaecol Oncol; 2004;25(2):225-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
  • PURPOSE: To evaluate the prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erbB-2 and cathepsin-D in epithelial ovarian cancer (EOC).
  • METHODS: We analyzed 100 patients with ovarian carcinoma, FIGO Stage IC-IV who underwent primary cytoreductive surgery and received adjuvant chemotherapy with cyclophosphamide and a platinum analogue (CP) (n = 46) or paclitaxel and a platinum analogue (TP) (n = 54).
  • Immunohistochemical expression was studied on paraffin-embedded tissue from the primary tumor.
  • FIGO stage (p = 0.006) and histology (p = 0.047) were the only independent prognostic factors for survival.
  • CONCLUSION: Bcl-2 and cathepsin D expression are associated with response to CP but not TP chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Cathepsin D / metabolism. Cyclophosphamide / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Platinum / administration & dosage. Predictive Value of Tests. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Receptor, ErbB-2 / metabolism. Survival Analysis. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15032288.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 49DFR088MY / Platinum; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.23.5 / Cathepsin D; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Abu-Musa A, Seoud M, Hannoun A: In vitro fertilization in a patient with ovarian cancer (stage IC) following conservative surgery and chemotherapy: a case report. Eur J Gynaecol Oncol; 2008;29(4):408-10
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro fertilization in a patient with ovarian cancer (stage IC) following conservative surgery and chemotherapy: a case report.
  • A 30-year-old female underwent left salpingo-oophorectomy followed by chemotherapy for Stage IC adenocarcinoma of the ovary.
  • Three years later she had ovarian hyperstimulation and in vitro fertilization (OH-IVF) resulting in a singleton pregnancy.
  • In conclusion, OH-IVF may be considered in young patients with early ovarian cancer treated with conservative surgery and chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Fertilization in Vitro. Ovarian Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Female. Humans. Paclitaxel / administration & dosage. Pregnancy. Pregnancy Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18714583.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Furukawa N: Solitary splenic metastasis of ovarian cancer. Arch Gynecol Obstet; 2007 Jun;275(6):499-502
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary splenic metastasis of ovarian cancer.
  • BACKGROUND: Solitary splenic metastasis occurs relatively rarely in ovarian cancer.
  • CASE REPORT: This report presents a patient in whom a solitary splenic metastasis was detected 9 years after diagnosis of stage Ic ovarian cancer.
  • The patient was a 59-year-old woman who was diagnosed with stage Ic ovarian serous cystadenocarcinoma in 1992, underwent postoperative chemotherapy, and exhibited no signs of recurrence in terms of clinical symptoms, markers and imaging findings.
  • The patient underwent a splenectomy and microscopy confirmed the splenic tumor to be of the same histological type as the ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / secondary. Ovarian Neoplasms / pathology. Splenic Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Splenectomy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096159.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


9. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer; 2000 Jun 1;88(11):2584-9
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
  • BACKGROUND: A retrospective review of treatment results comparing women with clear cell carcinoma of the ovary (CCC) with a group with serous adenocarcinoma of the ovary (SAC) was conducted.
  • METHODS: Between 1988-1998, 662 patients with epithelial ovarian carcinoma were identified through the medical records department and the tumor registry at 4 institutions.
  • All patients underwent staging laparotomy followed by platinum-based chemotherapy.
  • Distribution of the International Federation of Gynecology and Obstetrics (FIGO) disease stage, response to chemotherapy, and prognosis for patients with CCC were compared with the same values in patients with SAC.
  • RESULTS: Patients with CCC were significantly more likely to have FIGO Stage I disease than were patients with SAC (48.5% vs. 16.6%).
  • A high recurrence rate was noted in those patients with Stage IC CCC (37%).
  • In those patients with Stage IC disease, the survival rates for patients with CCC were lower than those for patients with SAC.
  • The 3-year and 5-year survival rates for Stage III CCC patients were significantly lower compared with Stage III SAC patients.
  • The response rate to platinum-based chemotherapy in patients with CCC was significantly lower than that in patients with SAC.
  • CONCLUSIONS: CCC is an intriguing histologic type of epithelial ovarian cancer that demonstrates a clinical behavior distinctly different from that of SAC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / mortality. Cystadenocarcinoma, Serous / mortality. Ovarian Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chi-Square Distribution. Female. Humans. Middle Aged. Neoplasm Staging. Platinum Compounds / therapeutic use. Retrospective Studies. Statistics, Nonparametric. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10861437.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds
  •  go-up   go-down


10. Sueblinvong T, Noophun P, Pataradool K, Suwanwela N, Phanthumchinda K, Tresukosol D: Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary. J Obstet Gynaecol Res; 2002 Apr;28(2):99-103
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.
  • A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic.
  • The clinicoradiologic features in this patient were consistent with posterior leukoencephalopathy, which is a rare complication of chemotherapy.
  • This syndrome has been previously reported following cisplatin-based chemotherapy.
  • Physicians should remain alert to the potential hazards of chemotherapy to the central nervous system.
  • Risks and benefits should be seriously considered before starting treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brain Diseases / chemically induced. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Anticonvulsants / therapeutic use. Bleomycin / adverse effects. Cisplatin / adverse effects. Electroencephalography. Female. Humans. Magnetic Resonance Imaging. Phenytoin / therapeutic use. Seizures / drug therapy. Seizures / etiology. Tomography, X-Ray Computed. Vinblastine / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. PHENYTOIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12078977.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anticonvulsants; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 6158TKW0C5 / Phenytoin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Borgfeldt C, Iosif C, Måsbäck A: Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer. Eur J Obstet Gynecol Reprod Biol; 2007 Sep;134(1):110-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer.
  • OBJECTIVE: The aim was to evaluate the outcome of fertility-sparing treatment in ovarian borderline tumors and early invasive ovarian cancer.
  • MATERIALS AND METHODS: All women diagnosed with an ovarian borderline tumor or early invasive ovarian cancer who were treated with fertility-sparing surgery at the University Hospital in Lund between 1988 and 2002 were identified and included in the study (n=23).
  • RESULTS: During the follow-up period of a median 92 months, range 11-185 months, no relapse was found in the patients with Stage 1a tumors, including both borderline tumors (n=12) and invasive well-differentiated (n=9) and moderately differentiated (n=1) ovarian cancers.
  • One patient with poorly differentiated ovarian cancer Stage 1c was 13 weeks' pregnant at the time of the primary operation.
  • At 37 weeks she had a cesarean section and the ovarian cancer was disseminated.
  • Chemotherapy was given but she died less than a year later.
  • None of the other patients received chemotherapy.
  • Prophylactic removal of the remaining ovary+/-hysterectomy was accepted in only in six of the women after fulfilling their desire to have more children.
  • CONCLUSIONS: Young women with Stage 1a epithelial ovarian cancer and borderline tumors do not have to give up their fertility in order to receive successful and safe treatment of their disease.
  • However, several of these patients do not accept the recommendation of prophylactic oophorectomy of the contralateral ovary and hysterectomy after completion of childbearing.
  • [MeSH-major] Adenocarcinoma / surgery. Fertility. Ovarian Neoplasms / surgery. Ovariectomy / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16859821.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


12. Gronlund B, Høgdall C, Christensen IJ, Engelholm SA, Hansen HH: Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum? Gynecol Oncol; 2004 Aug;94(2):409-15
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
  • OBJECTIVE: Recurrent ovarian carcinoma is considered an incurable disease and second-line chemotherapy is administered for extension of survival and palliation.
  • The impact of continued antineoplastic treatment in patients with stable disease without a demonstrable response is uncertain.
  • The aim of this analysis was to assess the value of a stabilization of the tumor size in second-line chemotherapy as an indicator of survival.
  • METHODS: Retrospective, single-institution study of 487 consecutive patients with primary epithelial ovarian carcinoma.
  • (1) FIGO stage IC-IV epithelial ovarian carcinoma;.
  • (2) first-line chemotherapy with Paclitaxel and a Platinum-compound;.
  • (3) refractory, persistent, or recurrent disease diagnosed by imaging methods; and (4) intravenous second-line chemotherapy with single Topotecan or Paclitaxel-Carboplatin.
  • Univariate and multivariate analyses of survival with the World Health Organization (WHO) tumor response parameter included as a time-dependent variable were performed.
  • CONCLUSION: In second-line chemotherapy of ovarian cancer, patients demonstrating SD have a survival benefit compared to patients with PD measured by the WHO tumor response criteria.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Topotecan / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15297181.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Sevelda P, Sevelda U, Denison U, Kaider A, Austrian Society of Gynecologic Oncology: Cytoprotection of amifostine (A) in ovarian cancer patients receiving paclitaxel/carboplatin (PC) first line chemotherapy in a multicenter phase III trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):5021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoprotection of amifostine (A) in ovarian cancer patients receiving paclitaxel/carboplatin (PC) first line chemotherapy in a multicenter phase III trial.
  • : 5021 Background: The primary objectives of the study were to evaluate, if A can prevent or reduce the WHO grade of haematological and non haematological toxicities induced by PC and to determine if A enables to adhere to the planned chemotherapy regimen (interval and dosage).
  • METHODS: 89 patients with primary epithelial ovarian cancer FIGO Stage IC - IV were entered into this prospective randomised phase III trial between 1998 and 2/2002.
  • In all patients first line chemotherapy of P 175 mg/m<sup>2</sup> i.v. within 3 hours day 1 and C AUC 5 on day 2 was planned for 6 cycles.
  • 41 patients received chemotherapy only.
  • RESULTS: The planned number of 40 patients in each treatment arm was achieved with 85 eligible patients.
  • This number was calculated to confirm a reduction of granulocytopenia by 50% and prevention of neurotoxicity difference in score increase by 2 units) in the A therapy arm.
  • Grad 3 and 4 granulocytopenia developed in 52,3 % of the patients in the A arm and 71,8 % in the control group (one-sided chi-square test X<sup>2</sup>= 3,32; p=0,034).
  • Neurotoxicity and all other toxicities were identical in both treatment arms.
  • Only nausea and vomiting was significantly increased in the A therapy arm with 20,5% grade 3 and 4 versus 5,1% in the control arm (chi-square test X<sup>2</sup>=4,22; p= 0,04).
  • Treatment delay was not significantly different in both groups.
  • At present we cannot recommend A as standard cytoprotective agent in ovarian cancer patients treated with this PC chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015515.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Muzii L, Palaia I, Sansone M, Calcagno M, Plotti F, Angioli R, Panici PB: Laparoscopic fertility-sparing staging in unexpected early stage ovarian malignancies. Fertil Steril; 2009 Jun;91(6):2632-7
MedlinePlus Health Information. consumer health - Ovarian Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic fertility-sparing staging in unexpected early stage ovarian malignancies.
  • OBJECTIVE: To assess feasibility and safety of fertility-sparing laparoscopic staging in women affected by unexpected ovarian cancer desiring to preserve their fertility.
  • PATIENT(S): Twenty-seven patients already operated on elsewhere for a presumably benign ovarian cyst.
  • RESULT(S): Histologic findings after first surgery: 12 low malignant potential neoplasms, 11 invasive epithelial ovarian carcinomas,1 sex-cord stromal, and 3 germ cell neoplasms.
  • Fertility-sparing staging consisted of exploration of the peritoneal cavity, peritoneal washing cytology, multiple peritoneal biopsies, omolateral adnexectomy (except in borderline tumors), omentectomy, omolateral or bilateral pelvic and aortic lymph node sampling (except in borderline tumors, well differentiated, mucinous, and granulosa cell (GC) neoplasms), endometrial biopsy, appendectomy in mucinous type.
  • Six patients received adjuvant platinum-based chemotherapy.
  • After a median follow-up of 20 months all patients are alive; one patient has FIGO stage Ic clear cell carcinoma, which recurred 8 months after surgery.
  • CONCLUSION(S): Laparoscopic fertility-sparing staging in early ovarian malignancies is feasible and safe in selected and counseled patients and should be performed in experienced gynecological oncology centers trained in endoscopic procedures.
  • [MeSH-major] Fertility / physiology. Laparoscopy / methods. Ovarian Cysts / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555237.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Sayedur Rahman M, Al-Sibai MH, Rahman J, Al-Suleiman SA, El-Yahia AR, Al-Mulhim AA, Al-Jama F: Ovarian carcinoma associated with pregnancy. A review of 9 cases. Acta Obstet Gynecol Scand; 2002 Mar;81(3):260-4
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinoma associated with pregnancy. A review of 9 cases.
  • BACKGROUND: The purpose of this study was to review patients with ovarian cancer in pregnancy, the effectiveness of the available methods of treatment and their prognosis.
  • METHODS: A retrospective review of all women diagnosed to have cancer of the ovary associated with pregnancy who delivered at the authors' hospitals between January 1976 and December 2000.
  • The demography, clinical presentation, time and mode of diagnosis, treatment, pregnancy outcome and maternal survival were noted.
  • RESULTS: The incidence of ovarian carcinoma in pregnancy in the series was 0.08/1000 deliveries.
  • Of the 9 patients, 7 had epithelial cancers; 4 serous cystadenocarcinoma, 2 mucinous cystadenocarcinomas and one undifferentiated cancer.
  • Six patients were in FIGO stage Ia, one Ic, one IIa.
  • One patient was in stage III.
  • Three patients had total abdominal hysterectomy, bilateral salpingo-oophorectomy and omentectomy followed by chemotherapy.
  • Debulking of the tumor was done in a patient in stage III with subsequent chemotherapy.
  • This patient died 13 months from the time of diagnosis of the tumor.
  • The overall 5-year survival rate in the series was 78% and 100% for stage Ia.
  • CONCLUSIONS: Association of ovarian cancer with pregnancy is a rare occurrence.
  • Early diagnosis and appropriate treatment offers the best prognosis for the patient.
  • The higher survival rates in the series was attributed to a larger number of patients in stage I of the disease and 2 patients with a germ cell tumor and dysgerminoma which have the best prognosis.
  • Aggressive postoperative chemotherapy also contributed to the better outcome.
  • [MeSH-major] Carcinoma / complications. Carcinoma / therapy. Ovarian Neoplasms / complications. Ovarian Neoplasms / therapy. Pregnancy Complications, Neoplastic / mortality. Pregnancy Complications, Neoplastic / therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11966485.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 15
  •  go-up   go-down


16. Ma SK, Zhang HT, Sun YC, Wu LY: [Synchronous primary cancers of the endometrium and ovary: review of 43 cases]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):690-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
  • OBJECTIVE: To investigate the clinical and pathological characteristics, treatment methods, and prognosis of synchronous primary cancers of the endometrium and ovary.
  • METHODS: The clinical data of 43 patients with synchronous primary cancers of the endometrium and ovary were retrospectively reviewed.
  • FIGO stages of endometrial carcinomas: IA 18 cases, IB 20 cases, IC 2 cases, IIA 3 cases; Stages of ovarian carcinomas: IA 19 cases, IB 4 cases, IC 7 cases, II 4 cases, III C 9 cases.
  • Twenty-four patients (55.8%) were in stage I both endometrial and ovarian carcinomas.
  • The predominant ovarian histology was endometrioid or mixed tumor with endometrioid components (30/43, 69.8%).
  • Postoperatively, 26 patients (60.5%) received adjuvant chemotherapy alone, 12 had chemotherapy plus radiotherapy, only one patient had radiation alone and the remaining 4 cases received no adjuvant treatment.
  • The 3- and 5-year survival rates of patients with both endometrioid and ovarian carcinomas were higher than that of those with non-endometrioid or mixed subtypes (93.8%, 82.0% vs. 79.7%, 69.0%).
  • The 3-year and 5-year survival rates of patients with early stage disease were better than those of the other patients (93.3%, 93.3% vs. 69.7%, 36.7%).
  • Recurrence developed in 15 patients (34.9%).
  • It was showed by univariate analysis that lower CA125 level, early FIGO stage, and adjuvant chemotherapy plus radiotherapy significantly and positively affect the 5-year survival rates, while only early FIGO stage and chemotherapy plus radiotherapy were revealed by multivariate analysis as independent prognostic factors.
  • CONCLUSION: Synchronous primary cancers of the endometrium and ovary are different from either primary endometrial carcinoma or ovarian cancer, while it can usually be detected in early stage and with a good prognosis.
  • Surgical treatment alone may be enough for early stage patients.
  • Chemotherapy plus radiotherapy may be necessary for advanced stage patients.
  • [MeSH-major] Carcinoma, Endometrioid. Endometrial Neoplasms. Hysterectomy / methods. Neoplasms, Multiple Primary. Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Proteins / metabolism. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173912.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NBR1 protein, human; 0 / Proteins
  •  go-up   go-down


17. Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y: Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol; 2007 Aug;12(4):256-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
  • BACKGROUND: Irinotecan hydrochloride, a topoisomerase I inhibitor, has been preliminarily recognized as an effective agent against clear cell carcinoma of the ovary (CCC), but there are few clinical data.
  • METHODS: One hundred and seventeen patients at International Federation of Gynecology and Obstetrics (FIGO) stages Ic (ascites/malignant washing) - IV were identified by scanning the medical records of ten Japanese hospitals.
  • RESULTS: There was no significant difference in median age, performance status, FIGO stage, rate of optimal cytoreduction, or follow-up period between the CPT-P and TC groups.
  • CONCLUSION: CPT-P showed a potential therapeutic effect, at least no less than that of TC therapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Ovarian Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):52-6 [16445610.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):723-8 [12079522.001]
  • [Cites] Cancer Lett. 1998 Jun 19;128(2):211-8 [9683285.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):735-40 [14675308.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6880-8 [16203778.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):197-203 [15262142.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2503-12 [14633622.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):412-7 [8774649.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):604-10 [1537625.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):893-7 [15894369.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):394-9 [12648592.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):285-91 [16516283.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2157-63 [8918409.001]
  • [Cites] Jpn J Clin Oncol. 1999 Sep;29(9):434-7 [10563197.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):327-31 [10671681.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):789-93 [8631015.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1138-50 [1904477.001]
  • [Cites] Jpn J Cancer Res. 1994 Sep;85(9):966-71 [7961127.001]
  • [Cites] Gynecol Oncol. 1993 May;49(2):250-4 [8504995.001]
  • (PMID = 17701003.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0H43101T0J / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


18. Iervolino P, Palmieri M, Rotondi M, D'Alessandro P, Iuliano R: [Borderline ovarian tumors. Retrospective analysis of 20 cases]. Minerva Ginecol; 2001 Feb;53(1 Suppl 1):97-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Borderline ovarian tumors. Retrospective analysis of 20 cases].
  • BACKGROUND: To evaluate the clinical features, the surgical management and outcome of 20 patients with stage-I borderline ovarian tumors.
  • METHODS: Twenty cases of FIGO stage-I ovarian tumors, aged from 31 to 58 years (mean 37 years) have been reviewed.
  • All informations of clinical stage, surgical intervention and prognosis were achieved by reviewing hospital records.
  • Minimal requirements for conservative management were adequate staging and complete information about the therapeutic options.
  • Factors important in the choice of the treatment were, age, wish to preserve fertility, histologic type and grade, and the stage of the tumour.
  • RESULTS: Eleven of the 20 patients (55%) were at stage IA, 6 cases (30%) were at stage IB, 3 cases (15%) were at stage IC.
  • Thirteen (65%) were with mucinous cystadenoma of borderline malignancy, 7 cases (35%) were of serous type.
  • One patient underwent enucleation of ovarian tumor and biopsy of contralateral ovary.
  • Any patient were treated with chemotherapy after operation.
  • With a median follow up of two years, we observed no recurrence of carcinoma in women treated conservatively or in those treated more radically.
  • CONCLUSIONS: Conservative surgery remains a therapeutic option in selected patients with borderline ovarian tumors.
  • Prolonged intensive follow-up is required for women treated conservatively for borderline malignant ovarian tumours.
  • [MeSH-major] Ovarian Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11526732.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


19. Khanfir A, Slimi Kallel L, Boudawarra T, Beyrouti MI, Frikha M: [Clinical and therapeutic results of a retrospective study about 62 cases of epithelial ovarian carcinomas]. Tunis Med; 2008 Apr;86(4):362-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and therapeutic results of a retrospective study about 62 cases of epithelial ovarian carcinomas].
  • AIM: To report retrospectively the therapeutic results and prognostic factors of epithelial ovarian carcinomas throughout a serie of 62 patients treated between 1993 and 2002.
  • Adjuvant ciplatin based poly chemotherapy (6 cycles) was indicated in FIGO stage Ic or more.
  • Patients with minimal surgery received 3 or 4 cycles of chemotherapy followed by an interval debulking surgery.
  • Overall survival was calculated according to Kaplan-Meier and univariate analysis done by the Log-Rank test for the following factors: age group, surgical excision, stage, histological type and presence or not of ascitis at diagnosis.
  • Adjuvant or neoadjuvant chemotherapy was given to 50 patients (93.5%).
  • Advanced stage was the only pejorative prognostic factor (P= 0.0002).
  • CONCLUSION: Incomplete surgery (minimal) and chemotherapy without taxanes based chemotherapy were associated with poor outcome in our patients.
  • Our study confirmed the importance of disease stage as a prognostic factor.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476140.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


20. Gueye A, Narducci F, Baranzelli MC, Collinet P, Farine O, Fournier C, Vinatier D, Leblanc E: [Malignant ovarian germ cell tumours: a trial of 36 cases]. Gynecol Obstet Fertil; 2007 May;35(5):406-19
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant ovarian germ cell tumours: a trial of 36 cases].
  • OBJECTIVE: With personal results and a review of the literature, we report the eventual interest of surgical staging in malignant ovarian germ cell tumours.
  • PATIENTS AND METHODS: This was a retrospective study of 36 patients (21.5-[8-61]) with malignant ovarian germ cell tumours between January 1984 and December 2004.
  • There were 4 groups: no 1--dysgerminoma only, no 2--immature teratoma, no 3--malignant ovarian germ cell tumours with secretion.
  • All the patients had a minimal follow up of 18 months after treatment.
  • RESULTS: Stages of FIGO were: group 1--IA n=2, IC n=2, IIB n=1, IIIA n=2, IIIC n=3; group 2--IA n=3 (G1, G2, G2), IC n=1 (G3); group 3--IA n=8, IC n=4, IIA n=1, IIIA n=1, IIIB n=3, IIIC n=5.
  • Three patients had neoadjuvant chemotherapy.
  • Twenty-six patients had adjuvant chemotherapy.
  • DISCUSSION AND CONCLUSION: Surgery in a young patient with malignant ovarian germ cells tumours must be conservative (adnexectomy) (preserving fertility and because of good prognostic).
  • In case of stage IA with part of dysgerminoma and/or immature teratoma and/or embryonal carcinoma certified by surgical staging, strict follow up could be organized (clinic, radiology, AFP, HCG).
  • In case of more than stage IA, chemotherapy is indicated after conservative surgery and surgical staging.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Infertility, Female / prevention & control. Neoplasms, Germ Cell and Embryonal / surgery. Ovarian Neoplasms / surgery. Ovariectomy / methods
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Female Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350873.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Wong HF, Low JJ, Chua Y, Busmanis I, Tay EH, Ho TH: Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. Int J Gynecol Cancer; 2007 Mar-Apr;17(2):342-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004.
  • Borderline ovarian tumors account for 15% of epithelial ovarian cancers and are different from invasive malignant carcinoma.
  • Majority are early stage, occurring in women in the reproductive age group, where fertility is important.
  • Majority of the cases (92%) were FIGO stage I (Ia, 75%; Ib, 1%; and Ic, 16%).
  • Seven (3.5%) patients were diagnosed as having stage II disease, six (2.5%) as stage IIIa, two (1%) as stage IIIb, and four (2%) as stage IIIc.
  • Primary surgical procedures undertaken were as follows: hysterectomy with bilateral salpingo-oophorectomy (52%), unilateral salpingo-oophorectomy (33%), or ovarian cystectomy (15%).
  • Adjuvant chemotherapy was administered in 13 patients (5.2% of cases), of which 4 patients were given chemotherapy only because of synchronous malignancies.
  • Overall mean time to recurrence was 59 months.
  • There were a total of five deaths (2.8%): three (1.5%) from invasive ovarian/peritoneal carcinoma and two from synchronous uterine malignancies.
  • It appears that surgical resection is the mainstay of treatment, with conservative surgery where fertility is desired or pelvic clearance if the family is complete.
  • The role of adjuvant chemotherapy is not established.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343573.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Xue DB, Ding LJ, Xia AL, Chen D, Xia HP, Teng XD, Xu ST, Zhang SJ, Ren XC: [Clinicopathologic study on 61 cases of uterine papillary serous carcinoma with or without adjuvant therapy]. Zhonghua Bing Li Xue Za Zhi; 2010 Oct;39(10):671-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study on 61 cases of uterine papillary serous carcinoma with or without adjuvant therapy].
  • OBJECTIVE: To study the clinicopathologic features of uterine papillary serous carcinoma (UPSC) and the roles of adjuvant therapy.
  • There were 27.9% cases in FIGO stage I (8.2% in stage IA, 14.8% in stage IB and 4.9% in stage IC), 9.8% in stage II, 32.8% in stage III and 29.5% in FIGO stage IV.
  • The histologic features were similar to those of the ovarian counterpart, with tumor cells containing the high-grade nuclei and arranged in complex papillae.
  • Fifty-six patients received adjuvant therapy.
  • The number of patients receiving adjuvant chemotherapy alone, adjuvant radiotherapy alone and combined adjuvant chemotherapy/radiotherapy were 42, 24 and 10, respectively.
  • The median survivals of the chemotherapy group and non-chemotherapy group (with or without radiotherapy) were 66.4 months and 32.8 months, respectively.
  • The tumor stage, lymph node status, lymphovascular permeation and depth of myometrial invasion were important prognostic factors.
  • Adjuvant chemotherapy for stage III/IV tumors or recurrent UPSC may have survival benefit.
  • [MeSH-major] Carcinoma, Papillary. Cystadenocarcinoma, Serous. Uterine Neoplasms
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Menopause. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant. Survival Rate

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176532.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Ma SK, Zhang HT, Wu LY, Liu LY: [Prognostic analysis of 88 patients with ovarian clear cell carcinoma]. Zhonghua Zhong Liu Za Zhi; 2007 Oct;29(10):784-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
  • OBJECTIVE: To investigate the clinical characteristics of clear cell carcinoma of the ovary and to compare the survival of the patients treated by three different chemotherapy regimens.
  • METHODS: Between 1984 and 2005, the clinical data of 88 surgically treated patients with clear cell carcinoma of the ovary were retrospectively analyzed.
  • Of the 88 patients, 55 (62.5%) had tumor in stage I, 2 in stage II, 22 in stage II, 3 in stage IV and 6 in indefinite stage.
  • Of 55 stage I patients, 20 received pelvic lymohadenectomy.
  • All patients were given postoperative chemotherapy, 43 patients received CAP/CP, 33 paclitaxel combination with carboplatinum/cisplatin (TC/TP) and 12 CPT-11 plus MMC.
  • During follow-up, 47 (53.4%) patients were found to have recurrence, it was 45.4% (25/55) in stage I patients including 29.6% (8/27) in stage I a + I b and 60.7% (17/28) in stage I c, 75.0% (18/24) in stage II + III and 4/6 in the indefinite FIGO stage.
  • The recurrences rate was 27.8% (5/18) in stage I patients with pelvic lymphadenectomy vs. 51.3% (19/37) in those without.
  • The overall 3- and 5-year survival rate of 88 patients was 48.7% and 40.9% , respectively, with 72.5% and 66.8% in stage I, 100.0% and 70.5% in stage Ia + Ib, 68.5% and 60.3% in stage Ic, 41.8% and 20.8% in stage II + III, 0 in stage IV (P < 0.05).
  • The 3- and 5-year survival in stage I with pelvic lymphadenectomy was 88.5% and 75.8% vs. 70.3% and 65.1% in those without (P < 0.05).
  • CONCLUSION: Our data show that ovarian clear cell cancer patient have a poor response to CAP/CP and may have a better response to TC/TP, especially to CPT-11 plus MMC.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms. Ovariectomy / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396695.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


24. Larbcharoensub N, Lertkhachonsuk AA, Rochanawutanon M: Secondary vaginal involvement following radical surgical treatment for a stage I ovarian adenocarcinoma arising in mature cystic teratoma. J Med Assoc Thai; 2007 Oct;90(10):2209-12
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary vaginal involvement following radical surgical treatment for a stage I ovarian adenocarcinoma arising in mature cystic teratoma.
  • BACKGROUND: Vaginal carcinoma represents 1-2% of all gynecologic malignancies.
  • She had had a history of right ovarian adenocarcinoma arising in MCT, FIGO stage IC, for 18 months' duration.
  • She received three courses of paclitaxel and carboplatin chemotherapy; however, she developed massive right pleural effusion with superior vena cava syndrome and finally succumbed to the disease, three months later.
  • This is the first case of ovarian adenocarcinoma arising in MCT with secondary vaginal involvement, presenting as postcoital vaginal bleeding.
  • [MeSH-major] Ovarian Neoplasms / pathology. Vaginal Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Carboplatin / therapeutic use. Disease Progression. Female. Humans. Immunohistochemistry. Paclitaxel / therapeutic use. Teratoma / surgery. Thailand

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18041444.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement